In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Cytokinetics Inc (CYTK), with a price target of $21. The company’s shares closed yesterday at $7.56.
Pantginis commented:
“Valuation and potential impediments to achieving it. We maintain our Buy rating and $21 price target. We highlight that omecamtiv, partnered globally with Amgen, drives the lion’s share of our current valuation (>80%). Our price target is based on our clinical net present value (NPV) model. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including the chance of success, peak sales estimates, and year of commercial launch.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -17.7% and a 27.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics Inc with a $14.25 average price target, which is an 88.5% upside from current levels. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $14 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.26 and a one-year low of $6.02. Currently, Cytokinetics Inc has an average volume of 367.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
